secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001104659-25-068530
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics prices $7M public offering of common stock and warrants
-------------------------------------------------------------------------

- Offering of 4,501,640 common shares and warrants to purchase 2,250,820 shares at $3.11 per set.
- Gross proceeds of $7.0M; net proceeds expected ~$6.3M after underwriting fees and expenses.
- Proceeds to fund clinical development of lead candidate GT-02287 for GBA1 Parkinson's disease.
- Warrants exercisable at $1.65 per share, immediately exercisable, expire in 5 years.
- Newbridge Securities sole book-runner; closing expected July 17, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925068530/0001104659-25-068530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925068530/tm2521066d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-068530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer